Alkermes
agents that induce immunogenic cell death may offer synergistic advantages in combination with combination with radiation chemotherapy or radiation immune inhibitors anti ongoing clinical trials anti growth factor pathway inhibitors tyrosine kinase inhibitors anti antibodies cytotoxic chemotherapies radiation activated cancer fighting cells pharmacotherapy alkermes | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
96 of 144
Similar slides by Alkermes
Investor Day
March 2021
Investor Day
March 2021
Related slides by other companies
Investor Presentation
October 2023
Investor Presentation
December 2021
IPO
September 2023
Investor Presentation
January 2024
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io